Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott

Seattle Genetics, Inc. SGEN today announced that it has entered into a collaboration agreement with Abbott ABT under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.